性别差异影响慢性自发性荨麻疹:女性负担更重且控制更差,尤其中年
基于国际CURE注册表4136例慢性自发性荨麻疹患者(女性72.4%),分析不同年龄组的性别差异。女性在血管性水肿、系统症状、睡眠障碍、生活质量受损及共病方面均高于男性,且所有药物类别控制率更低;51-65岁女性疾病负担和控制不佳尤为突出,而65岁以上女性差异不显著。
要点
- 女性CSU患者血管性水肿和系统症状发生率显著高于男性。
- 女性在所有药物类别中荨麻疹控制率均低于男性。
- 51-65岁女性疾病负担更重、控制更差,需重点关注。
核心结论
- 女性CSU患者疾病负担高于男性,且中年(51-65岁)女性尤为突出。
研究设计与样本
- 基于国际CURE注册表的真实世界研究,纳入4136例CSU患者,女性2994例(72.4%),来自29个国家58个中心。
- 通过在线平台标准化问卷收集数据,按年龄分组(<13、13-17、18-30、31-50、51-65、>65岁)比较性别差异。
主要发现
- 女性血管性水肿发生率59.6% vs 男性51.7%(p<0.001),系统症状34.6% vs 25.4%(p<0.001)。
- 女性睡眠障碍38.9% vs 32.5%(p<0.001),CU-Q2oL评分32 vs 27.7(p<0.001)。
- 女性在所有药物类别中荨麻疹控制率均低于男性(p<0.05)。
- 女性共病(哮喘、甲状腺疾病、肥胖、自身免疫病、胃肠道疾病、抑郁)更多(p<0.05)。
- 51-65岁女性血管性水肿、系统症状、生活质量受损、UCT评分低及急诊就诊多于男性(p<0.05),但>65岁女性差异不显著。
临床怎么用
- 临床应关注女性CSU患者,尤其31岁以上及51-65岁中年女性,评估疾病负担和控制情况。
- 对女性患者需更积极评估共病(如甲状腺疾病、自身免疫病、抑郁)并优化治疗以实现控制。
局限性
- 数据来自在线注册表,可能存在选择偏倚和信息偏倚。
- 未报告CSU诊断确认方法和应答率等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic spontaneous urticaria (CSU), a disease predominantly affecting females, has limited information available on its differences between females and males of varying ages. OBJECTIVES: To investigate sex differences in age groups regarding disease activity, comorbidities, quality of life (QoL) and treatment patterns in CSU patients. METHODS: We analysed Chronic Urticaria Registry (CURE) data, an international real-world registry for patients with chronic urticaria. Patients were recruited via an online platform using a standardized questionnaire. The data were analysed for demographics, age of onset, duration of urticaria, (Urticaria Activity Score [UAS], Urticaria Control Test [UCT], Chronic Urticaria Quality of Life Questionnaire [CU-Q2oL]), family history, systemic symptoms, aggravating factors, comorbidities, smoking and alcohol consumption, laboratory parameters, burden of disease, treatment distribution and response rates, compliance to treatment and adverse events. Comparisons were made among age groups <13, 13-17, 18-30, 31-50, 51-65 and >65 years. RESULTS: Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female. Statistically significant female predominance started at age 31 (<0.001). Compared with males, females showed higher rates of angioedema (59.6 vs. 51.7%; p < 0.001), systemic symptoms (34.6 vs. 25.4%; p < 0.001), sleep disturbance (38.9 vs. 32.5%; p < 0.001), QoL impairment (CU-Q2oL score 32 vs. 27.7; p < 0.001) and lower rates of urticaria control than males in all medication categories (p < 0.05 for all). Females had more concomitant diseases, including asthma, thyroid disease, obesity, autoimmune disease, gastrointestinal disease and depression (p < 0.05 for all). The disease was especially more burdensome and refractory in females aged 51-65 years than males, evidenced by more angioedema and systemic symptoms, worse QoL, lower UCT scores and more emergency visits (p < 0.05 for all). However, these differences were not prominent in the elderly females (>65 years). CONCLUSIONS: Compared with males, female CSU patients experience more burdensome disease, which gets worse in midlife. CLINICALTRIALS: gov (or equivalent) listing (if applicable None).
引用
- Kocatürk E, Salameh P, Asero R, et al. Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife-CURE insights. J Eur Acad Dermatol Venereol. 2025. PMID: 40965122. doi:10.1111/jdv.70027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。